Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility

RegulatoryPositive

AI Analysis

Summary

Gallant received FDA-CVM eligibility for expanded conditional approval pathway for its IV-delivered stem cell therapy targeting canine osteoarthritis, with a conditional approval target of 2028. The company reported promising pilot data for the therapy addressing a significant unmet need in veterinary medicine.

Clinical Trial Data

Outcome Details

Granted eligibility for expanded conditional approval by FDA-CVM for canine osteoarthritis stem cell therapy

Importance:6/10

Sentiment:

0.70

stem cell therapyveterinary medicineFDA conditional approvalcanine osteoarthritisIV-delivered

Related Companies

$SHWZ

Read the original article

Published by PR Newswire Biotech on May 6, 2026 12:52 PM

Read Original